Abnormal brain tryptophan metabolism and clinical correlates in tourette syndrome

Movement Disorders

Volumn 22, Issue 15, 2007, Pages 2256-2262

  Behen, Michael ^a   Chugani, Harry T ^a,b   Juhasz, Csaba ^a   Helder, Emily ^a   Ho, Albert ^a   Maqbool, Mohsin ^a   Rothermel, Robert D ^a   Perry, Jacquie ^a   Muzik, Otto ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Fronto striatal thalamic circuit; Neuroimaging; Neuropsychology; Positron emission tomography (PET); Serotonin; Tourette syndrome

Indexed keywords

DIAZEPAM; FENTANYL; METHYL TRYPTOPHAN C 11; PENTOBARBITAL; SEROTONIN; TRACER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; METABOLISM; NEUROIMAGING; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; TIC;

ADOLESCENT; BRAIN; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CHILD; CHILD, PRESCHOOL; CORPUS STRIATUM; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN; SEVERITY OF ILLNESS INDEX; THALAMUS; TOURETTE SYNDROME; TRYPTOPHAN;

EID: 38049054832     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21712     Document Type: Article

References (44)

1. Como PG. Neuropsychological function in Tourette syndrome. In: Cohen DJ, Jankovic J, Goetz CG, editors. Tourette syndrome, Advances in neurology, Vol. 85. Philadelphia: Lippincott Williams & Wilkins; 2001. p 103-111.
2. Berardelli A, Curra A, Fabbrini G, Gilio F, Manfredi M. Pathophysiology of tics and Tourette syndrome. J Neurol 2003;250:781-787.
3. Stern E, Silbersweig DA, Chee KY et al. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry 2000;57:741-748.
4. Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology 2002;27:92-104.
5. Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586.
6. Krause KH, Dresel S, Krause J, Kung HF, Tatsch K, Lochmuller H. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. J Neurol 2002;249:1116-1118.
7. Leckman JF, Anderson GM, Cohen DJ, et al. Whole blood serotonin and tryptophan levels in Tourette's disorder: effects of acute and chronic clinidine treatment. Life Sci 1984;35:2497-2503.
8. Leckman JF, Goodman WK, Anderson GA, et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995; 12:73-86.
9. Butler IJ, Koslow SH, Seifert WE, Caprioli RM, Singer HS. Biogenic amine metabolism in Tourette syndrome. Ann Neurol 1979;6:37-39.
10. Anderson GM, Pollak ES, Chatterjee D, et al. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 1992;58:123-133.
11. Muller-Vahl KR, Meyer GJ, Knapp WH, et al. Serotonin transporter binding in Tourette syndrome. Neurosci Lett 2005;385:120-125.
12. Heinz A, Knable MB, Wolf SS, et al. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 1998;51:1069-1074.
13. Haugbol S, Pinborg LH, Regeur L, et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int J Neuropsychopharmacol 2007;10(2):245-252.
14. Diksic M, Nagahiro S, Sourkes TL. Biological model for the in vivo measurement of rate of serotonin synthesis in the brain. J Neural Transm Suppl 1990;29:131-140.
15. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl- L-tryptophan. Synapse 1998;28:33-43.
16. Juhasz C, Chugani DC, Muzik O, et al. In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab 2006;26:345-357.
17. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonaustic children. Ann Neurol 1999;45:287-295.
18. Leckman JF, Towbin KE, Ore SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun R, Leckman JF, editors. Tourette syndrome and tic disorders: clinical understanding and treatment. Wiley: New York, NY; 1988.
19. Scahill L, Riddle MA, McSwiggan-Hardin, Ort SI, King RA, Goodman WK, Leckman JF. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Am J Child Adolesc Psychiatry 1997;36:844-852.
20. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
21. Reynolds CR, Kamphaus RW. The Behavioral Assessment Scales for Children. American Guidance Service 1992: Circle Pines, MN.
22. Muzik O, Chugani DC, Chakraborty P, Manger T, Chugani HT. Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo. J Cereb Bllod Flow Metab 1997;17:659-669.
23. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for 3 dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011-2018.
24. Winer BJ, Brown DR, Michels KM. Statistical principles in experimental design, 3rd ed. McGraw-Hill: New York, NY; 1991.
25. Bloch MH, Leckman JF, Zhu H, Peterson BS. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology 2005;65(8):1253-1258.
26. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999;38:86-94.
27. Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET Am J Psychiatry 2002;159:1329-1336.
28. Kates WR, Frederikse M, Mostofsky SH, et al. MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatry Res 2002;116:63-81.
29. Peterson BS, Staib L, Scahill L, et al. Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry 2001; 58:427-440.
30. Fredericksen KA, Cutting LE, Kates WR, et al. Disproportionate increases of white matter in right frontal lobe in Tourette syndrome. Neurology 2002;58:85-89.
31. Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology 1993;9:277-291.
32. Eidelberg D, Moeller JR, Antonini A, et al. The metabolic anatomy of Tourette's syndrome. Neurology 1997;48:927-934.
33. Braun AR, Randolph C, Stoetter B, et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study II. Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology 1995;13:151-168.
34. Singer HS, Reiss AL, Brown JE, et al. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology 1993;43(5):950-956.
35. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF. Functional deficits in basal ganglia of children with attention-deficit/ hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med 2000;6:470-473.
36. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:563-584.
37. Schrimsher GW, Billingsley RL, Jackson EF, Moore BD III. Caudate nucleus volume asymmetry predicts attention-deficit hyperactivity disorder (ADHD) symptomatology in children. J Child Neurol 2002;17:877-884.
38. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2003;27:605-613.
39. Singer HS. Neurobiology of Tourette syndrome. Neurol Clin 1997; 15(2):357-379.
40. Rommelspacher H, Strauss S. Effect of lesions of raphe nuclei on the activity of catecholaminergic and serotonergic neurones in various brain regions of the rat in vivo. J Neural Transm 1980; 49(1-2):51-62.
41. Bazzett TJ, Falik RC, Becker JB, Albin RL. Chronic intrastriatal administration of quinolinic acid produces transient nocturnal hypermotility in the rat. Brain Res Bull 1996;39:69-73.
42. Hernandez LF, Segovia G, Mora F. Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study. Neurochem Res 2003;28:1819-1827.
43. Beal MF, Ferrante RJ, Swatz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntigton's disease. J Neurosci 1991;11:1649-1659.
44. Goetz CG. Clonidine and clonazepam in Tourette syndrome. Rev Adv Neurol 1992;58:245-251.